Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.67 |
| ▸ | KCNMB4 | Q86W47 | 1/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.65 |
| ▸ | RXFP4 | Q8TDU9 | 5/20 | 0.60 |
| ▸ | RXFP3 | Q9NSD7 | 5/20 | 0.60 |
| ▸ | F11 | P03951 | 1/20 | 0.58 |
| ▸ | MC4R | P32245 | 2/20 | 0.58 |
| ▸ | MC1R | Q01726 | 2/20 | 0.58 |
| ▸ | KLK7 | P49862 | 1/20 | 0.57 |
| ▸ | INSR | P06213 | 1/20 | 0.54 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.54 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.54 |
| ▸ | TSLP | Q969D9 | 2/20 | 0.54 |
| ▸ | PRLHR | P49683 | 2/20 | 0.53 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.53 |
| ▸ | MC3R | P41968 | 1/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | F12 | P00748 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29993740 | 0.86 | RXFP1 (0.55) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| SCHEMBL29356518 | 0.81 | KCNMA1 (0.59) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| SCHEMBL29424808 | 0.80 | RXFP1 (0.67) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| SCHEMBL29389059 | 0.80 | KCNMA1 (0.66) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| SCHEMBL29438822 | 0.79 | KCNMA1 (0.66) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| SCHEMBL29438955 | 0.77 | MC4R (0.66) | KCNMA1KCNMB4RXFP1RXFP4RXFP3 | |
| SCHEMBL22861993 | 0.77 | TET2 (0.57) | F11TET2TET1TSLPSSTR2 | |
| SCHEMBL24919541 | 0.77 | TET2 (0.56) | F11TET2TET1TSLPF12 | |
| SCHEMBL22861964 | 0.77 | TET2 (0.56) | F11TET2TET1TSLPF12 | |
| SCHEMBL31211808 | 0.76 | TSLP (0.50) | KCNMA1KCNMB4TET2TET1TSLP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119185569-A | Sustained release delivery system comprising a traceless linker | 诺华股份有限公司 | 2024-12-27 | — | — | CN | claimed |
| US-20240002547-A1 | THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND USES THEREOF | AEBI LTD (IL) | 2024-01-04 | — | — | US | claimed |
| US-11236360-B2 | Adeno-associated viruses engineered for selectable tropism | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-02-01 | — | — | US | claimed |
| US-12606937-B2 | Humanized antibodies with ultralong complementary determining regions | TAURUS BIOSCIENCES, LLC (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260001922-A1 | PEPTIDES TARGETING SODIUM CHANNELS TO TREAT PAIN | UNIV CALIFORNIA (US) | 2026-01-01 | — | — | US | disclosed |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | NOVARTIS AG (CH) | 2025-10-07 | — | — | US | disclosed |
| WO-2025137555-A1 | POLYPEPTIDES THAT BIND TO NKP46 | OMNIAB, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-119185569-A | Sustained release delivery system comprising a traceless linker | 诺华股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240012004-A1 | INCREASED VOLTAGE-GATED SODIUM CHANNEL ALPHA PROTEIN SUBUNIT EXPRESSION THROUGH VIRAL 2A-MEDIATED CO-EXPRESSION OF NAV BETA SUBUNITS | MERCK SHARP & DOHME LLC (US) | 2024-01-11 | — | — | US | disclosed |
| US-20240002547-A1 | THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND USES THEREOF | AEBI LTD (IL) | 2024-01-04 | — | — | US | disclosed |
| US-20230287598-A1 | HUMANIZED ANTIBODIES WITH ULTRALONG COMPLEMENTARY DETERMINING REGIONS | TAURUS BIOSCIENCES, LLC | 2023-09-14 | — | — | US | disclosed |
| US-11739163-B2 | Therapeutic multi-targeting constructs and uses thereof | AEBI LTD. (IL) | 2023-08-29 | — | — | US | disclosed |
| US-20230201353-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | NOVARTIS AG (CH) | 2023-06-29 | — | — | US | disclosed |
| US-11530493-B2 | Humanized antibodies with ultralong complementary determining regions | TAURUS BIOSCIENCES, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2022108832-A1 | INCREASED VOLTAGE-GATED SODIUM CHANNEL ALPHA PROTEIN SUBUNIT EXPRESSION THROUGH VIRAL 2A-MEDIATED CO-EXPRESSION OF NAV BETA SUBUNITS | MERCK SHARP & DOHME CORP. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-11236360-B2 | Adeno-associated viruses engineered for selectable tropism | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606937-B2 | Humanized antibodies with ultralong complementary determining regions | IGLV6-57, FCGR3B, VSIR | KCNMA1 2682/4885KCNMB4 742/4885RXFP1 1234/4885 |
| US-20230201353-A1 | SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERS | ABCB11, ABCB1, GHRHR | KCNMA1 4420/4885KCNMB4 3598/4885RXFP1 714/4885 |
| US-11739163-B2 | Therapeutic multi-targeting constructs and uses thereof | CD47, GZMB, CD44 | KCNMA1 3460/4885KCNMB4 2969/4885RXFP1 2964/4885 |
| US-20260001922-A1 | PEPTIDES TARGETING SODIUM CHANNELS TO TREAT PAIN | TPX2, XBP1, SCN9A | KCNMA1 379/4885KCNMB4 233/4885RXFP1 129/4885 |
| US-12433949-B2 | Sustained release delivery systems comprising traceless linkers | ABCB11, ABCB1, GHRHR | KCNMA1 4420/4885KCNMB4 3598/4885RXFP1 714/4885 |
| US-20240002547-A1 | THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND USES THEREOF | CD47, GZMB, CD44 | KCNMA1 3460/4885KCNMB4 2969/4885RXFP1 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.